文拉法辛治疗非典型面痛患者的有效性和安全性研究

Efficacy and safety of venlafaxine in the treatment of patients with atypical facial pain

目的探讨文拉法辛治疗非典型面痛患者的有效性和安全性。方法回顾性选取2015年6月至2018年6月在首都医科大学附属北京天坛医院就诊的42例非典型面痛患者,均给予文拉法辛规律治疗。分别在患者治疗前以及治疗后1周、2周、1个月、2个月进行疼痛数字评分(NRS)、汉密尔顿抑郁量表(HAMD)和汉密尔顿焦虑量表(HAMA)测定,对短中期疗效、不良反应和并发症进行评价。结果治疗后1周、2周、1个月和2个月末疼痛缓解总有效率分别为9.52%(4/42)、83.33%(35/42)、90.48%(38/42)和100%(42/42)。治疗后1周NRS、HAMD及HAMA评分均低于治疗前,差异具有统计学意义(P<0.05);治疗后2周、1个月、2个月上述评分均进一步降低,显著低于治疗前,差异具有显著统计学意义(P<0.01)。治疗过程中无严重的不良反应和并发症发生。结论文拉法辛治疗非典型面痛患者安全有效,但远期疗效有待进一步观察。

Objective To evaluate the efficacy and safety of Venlafaxine in treating patients with atypical facial pain.Methods 42 patients with atypical facial pain admitted in Beijing Tiantan Hospital,Capital Medical University from June 2015 to June 2018 were treated with Venlafaxine.The numeric rating scales(NRS)of pain,Hamilton depression scale(HAMD)and Hamilton anxiety scale(HAMA)were measured before and after treatment,1 week,2 weeks,1 month and 2 months respectively.The short-term and mid-term efficacy,adverse reactions and complications were analyzed.Results The total effective rate of pain relief at 1 week,2 weeks,1 month and 2 months after treatment were 9.52%(4/42),83.33%(35/42),90.48%(38/42)和100%(42/42),respectively.NRS,HAMD and HAMA scores at 1 week after treatment were all lower than those before treatment,the differences were statistically significant(P<0.05),which were further decreased at 2 weeks,1 month and 2 months after treatment,and all were significantly lower than those before treatment,the differences were statistically significant(P<0.01).No serious adverse effects reactions or complications occurred during the treatment.Conclusion Venlafaxine is safe and effective in treating patients with atypical facial pain,but the long-term effect remains to be further observed.